$45.73
Near FV▼ -1.2% against the close used
Model range $4.03 – $66.76
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Bear$4.03Fair value$45.73Bull$66.76
FairClose
52-week traded range
52W low $32.1152W high $54.05
The 52-week range is measured from the stored price history, not estimated.
Trading close to the consensus fair value
CONMED Corporation closed at $46.30, 1.2% above the consensus fair value of $45.73 drawn from 9 valuation models.
Financial DNA score 37/100 — Average. P/E of 30.7x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
DCF Valuation
$66.76
+44.2%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=2.7%, r=10%, tg=3%, n=10yr
Graham Number
$34.26
-26.0%
√(22.5 × EPS × BVPS)
EPS=1.51, BVPS=34.55 · outside Graham range (P/E 30.7, P/B 1.3) — asset-light, treat as a rough floor
P/E Fair Value
$30.20
-34.8%
EPS × 20x (sector P/E)
EPS=1.51, Sector P/E=20x
Peter Lynch (PEG)
$4.03
-91.3%
EPS × Growth% (PEG = 1 is fair)
EPS=1.51, g=2.7%
EV/EBITDA
$43.56
-5.9%
(EBITDA × 11.3x − Net Debt) ÷ Shares
EBITDA=119.77M
Dividend Discount (DDM)
$8.43
-81.8%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=0.6, r=10%, g=2.7%
Book Value (P/B)
$7.50
-83.8%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=34.55, ROE=4.5%, g=3%, r=10%
Reverse DCF
$46.30
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 12.9% | Historical: 2.7%
Margin of Safety
$32.81
-29.1%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=43.74, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.